Haleon (HLN) Stock Price, Fundamentals & Analysis

What HLN does

Haleon (HLN) is a consumer healthcare stock listed on the London Stock Exchange. The company researches, manufactures, and sells products across oral care, vitamins and supplements, respiratory relief, pain management, and digestive health. Its brands include Sensodyne, Polident, Centrum, Theraflu, Voltaren, and TUMS, among others. Haleon operates in North America, Europe, the Middle East, Africa, Latin America, and Asia Pacific, and has a collaboration with Microsoft to scale digital, data, and AI capabilities across its business. It was formerly known as DRVW 2022 plc and changed its name in February 2022. In the broader healthcare landscape, peers include AstraZeneca (AZN), GSK plc (GSK), and Convatec (CTEC), while its exposure to drug manufacturing links it to companies such as Merck (MRK).

Key numbers explained

• 3.43 GBP is the current share price, the amount you would pay for one share at this moment.
• -0.64% is today's price change, showing the percentage move relative to the previous close.
• 30.14B GBP is the market capitalisation, the total value of all outstanding shares; it places Haleon among the larger companies on the London Stock Exchange stocks list.
• The trailing P/E ratio of 19 divides the current share price by the last 12 months' earnings per share (0.18 GBP), indicating how much investors pay for each pound of recent earnings.
• The forward P/E ratio of 15 uses expected future earnings, which can make the stock look cheaper if those expectations hold.
• 2.13% is the dividend yield, the annual dividend payment expressed as a percentage of the share price.
• 39% is the share of earnings paid out as dividends, showing what portion of profit goes to shareholders rather than being retained for growth or debt reduction.
• 0.25 is the beta, a measure of volatility relative to the market; a value below 1 suggests the stock tends to move less than the overall market.
• 3.18 – 4.16 is the 52-week price range, the lowest and highest price over the past year, with the current price sitting closer to the lower end.
• 4.4% is the price change over the last 52 weeks, the total return from one year ago to today, excluding dividends.
• 11.15 mld. GBP is the trailing 12-month revenue, the total sales the company generated.
• 2.2% is the year-over-year revenue growth, showing how much top-line sales have changed compared with the same period a year earlier.
• 14.6% is the profit margin, the percentage of revenue that remains as net profit after all expenses.
• 23.9% is the operating margin, which reflects profitability from core operations before interest and taxes.
• 10.1% is the return on equity, showing how effectively the company generates profit from shareholders' capital.
• 50.2% is the debt-to-equity ratio, comparing the company's total debt to its shareholders' equity.
• 185.85 is the price-to-book ratio, comparing the share price to the book value per share; a high ratio can indicate the market values the company above its accounting net assets.

What to watch

• Earnings reports, with the next scheduled for 30 iul. 2026, can move the share price depending on whether results meet, beat, or miss expectations.
• The ex-dividend date of 13 aug. 2026 determines which shareholders are eligible for the next dividend payment.
• Revenue growth of 2.2% and a profit margin of 14.6% are useful for tracking whether the company is expanding its top line while maintaining profitability.
• The debt-to-equity ratio of 50.2% is a general indicator of financial leverage; investors in healthcare stocks often compare this with peers such as Smith & Nephew (SN) or WuXi AppTec (603259).
• The beta of 0.25 suggests lower volatility than the broader market, which can appeal to investors seeking more stable exposure within the healthcare sector.